RECQL

ATP-dependent DNA helicase Q1 · P46063 · RECQL on Sugi Atlas →

889,852 patent compounds predicted against RECQL, 613,837 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Daunorubicin (SCHEMBL3041)	1.00	8/20
Daunorubicin (SCHEMBL4444)	1.00	8/20
Daunorubicin (SCHEMBL4445)	1.00	8/20
Carubicin (SCHEMBL4201)	0.98	8/20
Idarubicin (SCHEMBL4838)	0.98	8/20
Detorubicin (SCHEMBL8642)	0.81	8/20
Zorubicin (SCHEMBL4023)	0.80	8/20
Zorubicin (SCHEMBL4024)	0.80	8/20
Zorubicin (SCHEMBL8231)	0.79	8/20
Zorubicin (SCHEMBL8232)	0.79	8/20
Aclarubicin (SCHEMBL4532)	0.77	8/20
Aclarubicin (SCHEMBL4533)	0.77	8/20
SCHEMBL4015	0.73	8/20
Methacycline (SCHEMBL4014)	0.70	8/20
Methacycline (SCHEMBL4016)	0.70	8/20
Rodorubicin (SCHEMBL8693)	0.58	8/20
Epirubicin (SCHEMBL3165)	1.00	7/20
Doxorubicin (SCHEMBL3242)	1.00	7/20
Doxorubicin (SCHEMBL3243)	1.00	7/20
Idarubicin (SCHEMBL3750)	1.00	7/20

Clinical trials — most relevant to RECQL by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)	PHASE3	COMPLETED
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)	PHASE3	COMPLETED
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy	PHASE2	WITHDRAWN
A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa	PHASE2	COMPLETED
Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations	PHASE2	COMPLETED
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer	PHASE2	RECRUITING
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants	nan	RECRUITING
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study	nan	ENROLLING_BY_INVITATION
The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis	nan	COMPLETED
International Ataxia Rating Scale in Younger Patients	nan	COMPLETED
Studies of Children With Metabolic and Other Genetic Disorders	nan	COMPLETED
Evaluation of Children With Endocrine and Metabolic-Related Conditions	nan	RECRUITING
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants	nan	RECRUITING
Shwachman Diamond Syndrome Registry and Study	nan	RECRUITING
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base	nan	RECRUITING
Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study	nan	COMPLETED
A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials	nan	ACTIVE_NOT_RECRUITING
Prospective Genetic Study in Patients With Ovarian Insufficiency	nan	UNKNOWN
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study	nan	RECRUITING
Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.	nan	COMPLETED
The Natural History of Mitochondrial Diseases	nan	RECRUITING
International PPB/DICER1 Registry	nan	RECRUITING
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RECQL binder may also engage these)

Protein	Name	Similarity
Q5RF63	—	1.000	Q5RF63 →
Q6AYJ1	—	1.000	Q6AYJ1 →
A8WK63	—	1.000	A8WK63 →
Q9Z129	—	1.000	Q9Z129 →
Q9TXJ8	—	0.996	Q9TXJ8 →
Q9FT73	—	0.996	Q9FT73 →
A2RUV5	—	0.995	A2RUV5 →
O93530	—	0.992	O93530 →
Q5D892	—	0.992	Q5D892 →
POLQ	DNA polymerase theta	0.992	landscape →
B6DMK2	—	0.991	B6DMK2 →
O18475	—	0.991	O18475 →
O09053	—	0.991	O09053 →
Q7ZU90	—	0.990	Q7ZU90 →
Q6PCN7	—	0.989	Q6PCN7 →
D3Z4R1	—	0.988	D3Z4R1 →
Q9FT74	—	0.988	Q9FT74 →
B0XDC4	—	0.988	B0XDC4 →
B4NBB0	—	0.988	B4NBB0 →
Q9CXF7	—	0.988	Q9CXF7 →
Q5ZLN8	—	0.988	Q5ZLN8 →
Q2NL08	—	0.987	Q2NL08 →
Q5UPX0	—	0.987	Q5UPX0 →
Q8MNV7	—	0.987	Q8MNV7 →
Q8NHQ9	—	0.987	Q8NHQ9 →
A2PYH4	—	0.987	A2PYH4 →
B6ZLK2	—	0.987	B6ZLK2 →
Q5ZJM3	—	0.987	Q5ZJM3 →
B2RR83	—	0.987	B2RR83 →
Q8NDG6	—	0.987	Q8NDG6 →